Compare Johnson & Johnson (JNJ) vs Workday Inc (WDAY) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Workday (WDAY) trades at $146.92, up 1.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $151.36. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $2.62. Revenue grew to $8.45 billion in 2025, though net income margin compressed to 6.22% from 19.02% in 2024. Positive sentiment is driven by AI product expansion, but a lawsuit over AI bias and net cash outflows present headwinds.

WDAY offers growth potential with strong subscription revenue and AI-driven deal expansion, yet high P/E of 45.1 suggests premium valuation. Risks include competitive pressures, regulatory scrutiny, and reliance on enterprise spending. Analyst consensus is bullish with 55.55% buy ratings, but investors should monitor execution on profitability and legal challenges.